Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-301, CDX-1140, and PLD in Metastatic HER2 Negative Breast Cancer
NCT05029999Phase 1Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2022
- Primary completion
- Apr 2028
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CDX-1140 and Flt3 ligand in breast cancer (2 cohorts), sponsored by UT Southwestern Medical Center. Primary endpoint: Dose Limiting Toxicity at 12 months. Started Apr 2022; status: recruiting.
02
Drugs
CDX-1140Flt3 ligand
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05029999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029999.